Sacituzumab tirumotecan for advanced kidney or bladder cancers
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced kidney or bladder cancers that have not responded to standard treatments. The drug targets a protein on cancer cells to deliver treatment directly, potentially slowing or stopping tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of advanced papillary kidney cancer or a type of bladder cancer with variant histology (including several rare subtypes).
- Your cancer must have progressed after standard treatments, or no standard treatment options are available.
- You must have at least one measurable tumor that can be assessed by imaging.
- You must be 18 years or older and have a good performance status (able to care for yourself and be up and about).
- You must provide a tumor tissue sample (archived or fresh biopsy) for testing.
- Your organ function must be adequate, as shown by blood tests, and you must have recovered from side effects of prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a new drug called sacituzumab tirumotecan for people with recurrent or metastatic adenoid cystic carcinoma or papillary thyroid carcinoma. The drug works by targeting a protein on cancer cells to deliver treatment directly, which may help shrink tumors or slow their growth.
This trial tests a new drug called sacituzumab tirumotecan for people with advanced bile duct cancer that has grown after previous treatment. The drug targets a protein called TROP2 on cancer cells and may help shrink tumors or slow the disease.
Hear when a new Papillary Renal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.